Biogen, Inc. (BIIB)
218.11
+1.33
(+0.61%)
USD |
NASDAQ |
Aug 24, 16:00
218.11
0.00 (0.00%)
After-Hours: 20:00
Biogen Enterprise Value : 39.09B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 39.09B |
| August 20, 2026 | 38.73B |
| August 19, 2026 | 39.79B |
| August 18, 2026 | 38.46B |
| August 17, 2026 | 37.96B |
| August 14, 2026 | 38.06B |
| August 13, 2026 | 38.18B |
| August 12, 2026 | 37.92B |
| August 11, 2026 | 37.18B |
| August 10, 2026 | 37.66B |
| August 07, 2026 | 37.78B |
| August 06, 2026 | 37.54B |
| August 05, 2026 | 37.59B |
| August 04, 2026 | 37.86B |
| August 03, 2026 | 36.88B |
| July 31, 2026 | 37.05B |
| July 30, 2026 | 37.78B |
| July 29, 2026 | 37.97B |
| July 28, 2026 | 37.44B |
| July 27, 2026 | 36.63B |
| July 24, 2026 | 36.93B |
| July 23, 2026 | 36.70B |
| July 22, 2026 | 36.28B |
| July 21, 2026 | 37.08B |
| July 20, 2026 | 36.60B |
| Date | Value |
|---|---|
| July 17, 2026 | 37.49B |
| July 16, 2026 | 37.93B |
| July 15, 2026 | 36.20B |
| July 14, 2026 | 35.42B |
| July 13, 2026 | 37.94B |
| July 10, 2026 | 36.48B |
| July 09, 2026 | 36.45B |
| July 08, 2026 | 36.66B |
| July 07, 2026 | 37.45B |
| July 06, 2026 | 37.86B |
| July 02, 2026 | 38.99B |
| July 01, 2026 | 38.05B |
| June 30, 2026 | 38.98B |
| June 29, 2026 | 34.25B |
| June 26, 2026 | 34.17B |
| June 25, 2026 | 32.09B |
| June 24, 2026 | 31.74B |
| June 23, 2026 | 31.38B |
| June 22, 2026 | 31.76B |
| June 18, 2026 | 31.29B |
| June 17, 2026 | 31.60B |
| June 16, 2026 | 31.15B |
| June 15, 2026 | 31.60B |
| June 12, 2026 | 31.81B |
| June 11, 2026 | 31.79B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 10.03B |
| AbbVie, Inc. | 532.50B |
| Gilead Sciences, Inc. | 202.61B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
| Amgen, Inc. | 280.82B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 97.50M |
| Revenue (Quarterly) | 2.622B |
| Total Expenses (Quarterly) | 2.525B |
| EPS Diluted (Quarterly) | 0.6557 |
| Gross Profit Margin (Quarterly) | 61.37% |
| Profit Margin (Quarterly) | 3.72% |
| Earnings Yield | 2.59% |
| Operating Earnings Yield | 5.85% |
| Normalized Earnings Yield | 4.189 |